Suppr超能文献

无创通气在治疗心源性休克中的有效性和安全性。

Effectiveness and safety of non-invasive ventilation in the management of cardiogenic shock.

机构信息

Intensive Care Unit, Morales Meseguer Hospital, Murcia, Spain.

Sleep and Non-invasive Ventilation Unit, Thorax Department, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal; ISAMB, Instituto de Saúde Ambiental da Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal.

出版信息

Rev Port Cardiol. 2024 May;43(5):259-273. doi: 10.1016/j.repc.2023.08.006. Epub 2023 Nov 8.

Abstract

INTRODUCTION AND OBJECTIVES

Cardiogenic shock (CS) has long been considered a contraindication for the use of non-invasive ventilation (NIV). The main objective of this study was to analyze the effectiveness, measured as NIV success, in patients with respiratory failure due to CS. As secondary objective, we studied risk factors for NIV failure and compared the outcome of patients treated with NIV versus invasive mechanical ventilation (IMV).

METHODS

Retrospective study on a prospective database, over a period of 25 years, of all consecutively patients admitted to an intensive care unit, with a diagnosis of CS and treated with NIV. A comparison was made between patients on NIV and patients on IMV using propensity score matching analysis.

RESULTS

Three hundred patients were included, mean age 73.8 years, mean SAPS II 49. The main cause of CS was acute myocardial infarction (AMI): 164 (54.7%). NIV failure occurred in 153 (51%) cases. Independent factors for NIV failure included D/E stages of CS, AMI, NIV related complications, and being transferred from the ward. In the propensity analysis, hospital mortality (OR 1.69, 95% CI 1.09-2.63) and 1 year mortality (OR 1.61, 95% CI 1.04-2.51) was higher in IMV. Mortality was lower with NIV (vs. EIT-IMV) in C stage (10.1% vs. 32.9%; p<0.001) but did not differ in D stage or E stage.

CONCLUSIONS

NIV seems to be relatively effective and safe in the treatment of early-stage CS.

摘要

引言和目的

心源性休克(CS)长期以来被认为是使用无创通气(NIV)的禁忌证。本研究的主要目的是分析因 CS 导致呼吸衰竭患者使用 NIV 的效果,以 NIV 成功为衡量标准。次要目标是研究 NIV 失败的风险因素,并比较接受 NIV 治疗与接受有创机械通气(IMV)治疗的患者的结局。

方法

这是一项回顾性研究,对 25 年来连续入住重症监护病房的 CS 患者进行前瞻性数据库分析,对所有患者均给予 NIV 治疗。通过倾向评分匹配分析,比较 NIV 组和 IMV 组患者的结果。

结果

共纳入 300 例患者,平均年龄为 73.8 岁,平均 SAPS II 为 49。CS 的主要病因是急性心肌梗死(AMI):164 例(54.7%)。153 例(51%)患者发生 NIV 失败。NIV 失败的独立因素包括 CS 的 D/E 期、AMI、NIV 相关并发症以及从病房转来。在倾向分析中,IMV 组的住院死亡率(OR 1.69,95%CI 1.09-2.63)和 1 年死亡率(OR 1.61,95%CI 1.04-2.51)均较高。在 C 期,NIV 组(10.1%)的死亡率低于 EIT-IMV 组(32.9%;p<0.001),但在 D 期或 E 期,死亡率无差异。

结论

NIV 似乎在治疗早期 CS 时相对有效且安全。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验